← Eichor
Study identifier: NCT05626400 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Clinical Study of Senl-T7 CAR T Cells in the Treatment of Relapsed and Refractory CD7+ Acute T-ALL/T-LBL

Condition: T-cell Acute Lymphoblastic Leukemia/Lymphoma  ·  Sponsor: Hebei Senlang Biotechnology Inc., Ltd.

PhaseNA
Planned participants100
Who can joinAll sexes, 2 Years to 70 Years
Healthy volunteersNo

About this study

This is an open, prospective, dose-escalation clinical study to evaluate the safety and efficacy of Senl-T7 in patients with relapsed or refractory CD7+ acute T lymphoblastic leukemia or T lymphoblastic lymphoma.Meanwhile, PK/PD indexes of Senl-T7 were collected.

This description comes directly from the study's public registry record.

Talk to the study team

Xian Zhang  ·  008618611636172  ·  xian_zhang@126.com

Jianqiang Li, MD, PhD  ·  008615511369555  ·  limmune@gmail.com

Always discuss trial participation with your own doctor first.

Locations (1)

Hebei yanda HospitalBeijingcun, Hebei, ChinaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05626400